阿帕替尼在晚期非小细胞肺癌的临床疗效观察

Clinical Efficacy of Apatinib in Advanced Non-small Cell Lung Cancer

目的探讨阿帕替尼在晚期非小细胞肺癌(NSCLC)中临床疗效。方法选取56例晚期NSCLC,给予阿帕替尼500mg/d治疗,直到病情进展或不可耐受副作用而停药,通过影像学检查及肿瘤标志物评价疗效,并对用药安全性做出评估。结果评估了50例患者的疗效:平均无进展生存期(PFS)为3.14月,客观有效率(ORR)为16.0%,疾病控制率(DCR)为68.0%。治疗前后血清VEGF无明显变化,差异无统计学意义;血清CEA及CYFRA211显著下降,差异有统计学意义。不同ECOG评分患者中位PFS差异有统计学意义(P<0.05),性别、年龄、是否联合化疗均无统计学意义(P>0.05)。不良反应经停药或积极治疗后可控。结论阿帕替尼治疗晚期NSCLC安全有效,能够延长晚期NSCLC无进展生存时间,对晚期NSCLC治疗具有重要意义。

Objective To investigate the clinical efficacy of apatinib in advanced non-small cell lung cancer(NSCLC).Methods 56 patients with advanced non-small cell lung cancer who failed in second-line treatment were treated with Apatinib 500 mg/d until the condition progressed or the side effects could not be tolerated.The effect was evaluated by imaging and tumor markers.Results The efficacy of 50 patients was evaluated:the average progressive survival period(PFS)was 3.14 months,the objective effective rate(ORR)was 16.0%,and the disease control rate(DCR)was 68.0%.The serum VEGF did not change significantly before and after treatment,and the difference was not statistically significant.Serum CEA and CYFRA211 decreased significantly,and the difference was statistically significant.The difference in the median PFS of patients with different ECOG scores was statistically significant(P<0.05),and there was no statistical significance in sex,age,and combination chemotherapy(P>0.05).Adverse reactions can be controlled after drug withdrawal or aggressive treatment.Conclusion Apatinib treatment of advanced NSCLC is safe and effective,can prolong advanced NSCLC without progress survival time,and has important significance for advanced NSCLC treatment.